# France Structural Heart Devices Market > France Structural Heart Devices Market Research Report: By Type (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) andBy Procedure (Replacement Procedures, Repair Procedures) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.67% - **2024:** $ 34.65 Million - **2025:** $ 36.96 Million - **2035:** $ 70.5 Million - **Key Players:** Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US) **Report ID:** MRFR/MED/55138-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/france-structural-heart-devices-market-56904 --- ## Market Summary ## **France Structural Heart Devices Market Overview****:** As per MRFR analysis, the France Structural Heart Devices Market Size was estimated at 35.78 (USD Million) in 2024.The France Structural Heart Devices Market Industry is expected to grow from 38.81(USD Million) in 2025 to 171 (USD Million) by 2035. The France Structural Heart Devices Market CAGR (growth rate) is expected to be around 14.433% during the forecast period (2025 - 2035). ### **Key France Structural Heart Devices Market Trends Highlighted** The France Structural Heart Devices Market is experiencing significant trends driven by various factors influencing both healthcare providers and patients. A notable market driver is the increasing prevalence of cardiovascular diseases in France, which has been a growing concern for the French healthcare system. The country's health policies emphasize improved patient outcomes, prompting hospitals to adopt advanced medical technologies, including structural heart devices.  Furthermore, the aging population in France is contributing to a rising demand for minimally invasive cardiac procedures, which are often facilitated by these innovative devices.Opportunities exist for manufacturers and healthcare providers to collaborate on developing tailored solutions that cater specifically to the needs of the French population.  The French government supports research and development in medical technology, providing a conducive environment for innovation in structural heart devices. This focus on enhancing healthcare technology can lead to the introduction of novel products designed to improve the quality of life for patients suffering from heart conditions. Recent trends indicate a shift towards greater acceptance of transcatheter therapies in France, which allows for less invasive treatments for heart valve issues.This trend aligns with a broader movement within the healthcare sector towards personalization and precision medicine, ensuring that patients receive treatments best suited to their individual health profiles.  Moreover, there is a growing emphasis on remote monitoring solutions in cardiology, enhancing patient management and follow-up care. In summary, the France Structural Heart Devices Market is evolving rapidly due to increasing cardiovascular health issues, advancements in medical technology, and supportive healthcare policies, presenting a variety of opportunities for growth and innovation in this vital sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **France Structural Heart Devices Market Drivers** ### **Aging Population and Increasing Prevalence of Cardiovascular Diseases** The France Structural Heart Devices Market Industry is significantly driven by the country's aging population, which is projected to reach approximately 23.6% of the total population over 60 years by 2030. This demographic shift leads to an increased prevalence of cardiovascular diseases, as age is a significant risk factor. According to the French Ministry of Health, about 1.5 million people in France are currently living with heart disease, and this number is expected to rise.Role-model learners like the French Cardiology Society are already working towards promoting awareness and treatment options, which in turn increases the demand for structural heart devices aimed at aortic stenosis and heart valve repair. ### **Technological Advancements in Medical Devices** Innovations in medical technology are revolutionizing the France Structural Heart Devices Market Industry by enabling the development of minimally invasive and more effective heart devices. For instance, the introduction of advanced transcatheter techniques has resulted in a higher success rate in valve replacements. Some leading corporations in the field, like Medtronic and Boston Scientific, are investing heavily in Research and Development (R&D).According to the French Ministry of Economy, the medical device sector accounted for close to 10 billion Euros in revenue in 2022, with a growing segment attributed to structural heart devices. These advancements are expected to improve patient outcomes and promote wider adoption of these technologies across healthcare facilities. ### **Government Initiatives and Healthcare Investments** Government policies in France are increasingly focusing on improving heart health care and providing comprehensive cardiovascular treatment. The French government has prioritized investments in healthcare infrastructure, with policies aimed at enhancing accessibility to advanced treatments in rural and urban areas. The annual Health Budget 2023 outlines an allocation of over 2 billion Euros for cardiology-specific programs, which directly influences the growth of the France Structural Heart Devices Market Industry.Additionally, partnerships with major healthcare providers and advocacy groups, such as the French Federation of Cardiology, amplify the reach and effectiveness of these initiatives by promoting new guidelines and best practice protocols in patient care. ## **France Structural Heart Devices Market Segment Insights****:** ### **Structural Heart Devices Market Type Insights** The France Structural Heart Devices Market, categorized under the 'Type' segment, encompasses various essential devices that play a crucial role in the management of structural heart diseases. Among these, Heart Valve Devices are notably significant due to their wide application in treating conditions such as aortic stenosis and mitral regurgitation, which are prevalent in the aging population of France. The advancements in bioprosthetic materials and minimally invasive techniques have further boosted their uptake.  Annuloplasty Rings are critical as they are designed to support and stabilize valve annuli, thereby enhancing the surgical outcomes for patients undergoing valve repair procedures.Their integration in surgical frameworks aligns well with the increasing trend towards less invasive cardiac interventions, enhancing recovery times and reducing hospital stays. Occluders, another vital category, have gained momentum as they provide effective solutions for conditions like atrial septal defects, thereby preventing complications such as stroke. The reliability and efficacy of these devices contribute significantly to their acceptance among practitioners in France. Delivery Systems facilitate the implementation of these devices, ensuring precise placements and minimizing procedural complications, which has become increasingly important in the contemporary landscape of cardiac interventions.The focus on improving patient outcomes ties in well with the market trends emphasizing minimally invasive options. As the France Structural Heart Devices Market continues to evolve, the interplay between these different types of devices remains pivotal in shaping treatment paradigms, underscoring their importance in addressing the growing health needs related to cardiovascular diseases in the French population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Structural Heart Devices Market Indication Insights** The France Structural Heart Devices Market is experiencing notable growth, particularly in the indication segments of Valvular Heart Disease and Cardiomyopathy. Valvular Heart Disease is a significant concern within the country, driven by a rising aging population and increasing prevalence of lifestyle-related cardiovascular conditions. This segment plays a critical role as advancements in device technology have led to more effective minimally invasive treatment options, improving patient outcomes. Cardiomyopathy is also a prominent area of focus, as its management continues to evolve with innovative therapies that address complex heart muscle disorders. Both segments contribute significantly to the overall market expansion, with increasing investments in Research and Development aimed at enhancing treatment effectiveness and patient quality of life. Additionally, regulatory bodies in France are supporting initiatives that promote research and the adoption of new technologies, further bolstering the growth potential of these indication segments. The combination of demographic trends, innovative therapy designs, and supportive regulatory frameworks makes the Indication segment a pivotal aspect of the France Structural Heart Devices Market. ### **Structural Heart Devices Market Procedure Insights** The France Structural Heart Devices Market has been increasingly centered around various medical procedures, particularly Replacement Procedures and Repair Procedures, which play a crucial role in addressing heart-related ailments. Replacement Procedures typically involve substituting damaged or diseased heart valves, offering a solution for patients suffering from valvular heart disease. This segment tends to dominate the market due to the growing prevalence of such conditions, driven by an aging population and rising healthcare awareness.  Meanwhile, Repair Procedures are pivotal in minimally invasive interventions, improving the quality of life for patients with structural heart defects.Both procedures benefit from advancements in technology, such as improved device designs and enhanced surgical techniques, leading to greater patient outcomes. The synergy between these procedures underscores their importance in the broader landscape of cardiovascular treatment, fulfilling the increasing demand for effective heart care solutions in France. Additionally, the focus on patient-centric approaches and personalized healthcare further accentuates the significance of these procedures within the France Structural Heart Devices Market. ## **France Structural Heart Devices Market Key Players and Competitive Insights****:** The France Structural Heart Devices Market is characterized by a dynamic competitive landscape driven by technological advancements and increasing emphasis on minimally invasive procedures. This market encompasses a variety of devices such as valves, closure devices, and other therapeutic options designed for the treatment of structural heart diseases. As healthcare providers and patients alike seek innovative solutions that can improve patient outcomes, the market is witnessing growing investment from both established and emerging players.  The competitive insights reveal a focus on research and development, strategic collaboration, and expansion of distribution networks to capture a larger share of this evolving market. Regulatory dynamics also play a crucial role in shaping the competitive environment, affecting product approval timelines and market entry strategies.CryoLife has established a notable presence within the France Structural Heart Devices Market, leveraging its innovative therapeutic technologies to enhance patient treatment options. The company is celebrated for its strengths in developing advanced surgical and interventional solutions aimed at treating various cardiovascular conditions.  CryoLife's commitment to quality and patient safety has positioned it favorably among healthcare professionals in France. The reliability of its products, supported by extensive clinical data, has driven Trust and loyalty from healthcare providers. Furthermore, CryoLife's strategic partnerships and collaborations with healthcare institutions in France facilitate the ongoing enhancement of its offerings, ensuring the company remains at the forefront of providing high-quality structural heart solutions in this competitive market.Heartware International has carved out a significant niche in the France Structural Heart Devices Market, particularly known for its cutting-edge ventricular assist devices (VADs) designed for patients with advanced heart failure.  The company focuses on delivering innovative solutions that not only extend patients' life expectancy but also improve their overall quality of life. Heartware International emphasizes research and development, contributing to a diverse product portfolio that addresses varying patient needs within the structural heart space. Its robust market presence in France is bolstered by strategic mergers and acquisitions aimed at augmenting its technological capabilities and market share. Such initiatives allow Heartware International to effectively expand its reach and influence within the French market, continuing to reinforce its strengths as a leader in the realm of heart support devices that enhance surgical outcomes and advance treatment protocols for structural heart challenges. ### **Key Companies in the France Structural Heart Devices Market Include:** - CryoLife - Heartware International - Vascular Solutions - Terumo Corporation - Edwards Lifesciences - CardioFocus - Teleflex - MicroPort Scientific Corporation - Boston Scientific - Cardiac Dimensions - LivaNova - AtriCure - Medtronic - Abbott Laboratories - Biosense Webster ## **France Structural Heart Devices Market Industry Developments** The France Structural Heart Devices Market has seen significant developments recently, with major companies like Edwards Lifesciences, Medtronic, and Boston Scientific continuing to innovate their product lines. In August 2023, Edwards Lifesciences announced the launch of a next-generation heart valve device tailored for patients with structural heart issues, highlighting its commitment to improving patient outcomes in France.  Meanwhile, Medtronic has expanded its transcatheter technologies, focusing on minimally invasive procedures that are gaining traction in French healthcare settings. Moreover, mergers and acquisitions have played a vital role in shaping the market landscape. In September 2023, Boston Scientific acquired a prominent local manufacturer of structural heart devices, combining their technologies to enhance treatment options in France.  The overall valuation of the market has been bolstered by these strategic moves, reflecting a growth trajectory amid increasing demand for advanced cardiac care. Additionally, government initiatives, including funding for innovative healthcare solutions, are further propelling the market forward, creating a robust environment for research and development in this specialized field, which has shown rapid advancements over the last few years. ## **France Structural Heart Devices Market Segmentation Insights** ### **Structural Heart Devices Market Type****Outlook** - Heart Valve Devices - Annuloplasty Rings - Occluders - Delivery Systems ### **Structural Heart Devices Market Indication****Outlook** - Valvular Heart Disease - Cardiomyopathy ### **Structural Heart Devices Market Procedure****Outlook** - Replacement Procedures - Repair Procedures -   ## Market Drivers ### Growing Awareness and Education There is a notable increase in awareness and education regarding cardiovascular health in France, which is positively impacting the structural heart-devices market. Public health campaigns and initiatives aimed at educating the population about heart disease risks and prevention strategies are becoming more prevalent. This heightened awareness is leading to earlier diagnosis and treatment of cardiovascular conditions, thereby increasing the demand for structural heart devices. Healthcare professionals are also receiving enhanced training on the latest technologies and treatment options, further driving the market. As patients become more informed about their treatment choices, the structural heart-devices market is likely to experience growth, reflecting a shift towards proactive healthcare management. ### Increased Healthcare Expenditure The rise in healthcare expenditure in France is a significant driver for the structural heart-devices market. The French government has been increasing its healthcare budget, with spending projected to reach approximately €200 billion by 2025. This financial commitment reflects a prioritization of advanced medical technologies and treatments, particularly in the field of cardiology. As hospitals and healthcare facilities receive more funding, they are likely to invest in state-of-the-art structural heart devices to enhance patient care. This trend not only supports the growth of the market but also encourages competition among manufacturers to provide innovative solutions. Consequently, the structural heart-devices market is poised for expansion, driven by the increasing availability of resources and a focus on improving healthcare outcomes. ### Supportive Regulatory Environment The regulatory environment in France is becoming increasingly supportive of innovations in the structural heart-devices market. Regulatory bodies are streamlining approval processes for new medical devices, which facilitates quicker access to advanced treatments for patients. This supportive framework encourages manufacturers to invest in research and development, knowing that their products can reach the market more efficiently. Additionally, the French government is actively promoting initiatives that foster collaboration between industry stakeholders and regulatory agencies, enhancing the overall ecosystem for medical device innovation. As a result, the structural heart-devices market is expected to benefit from a more favorable regulatory landscape, which could lead to an influx of new products and technologies in the coming years. ### Rising Prevalence of Cardiovascular Diseases The increasing incidence of cardiovascular diseases in France is a primary driver for the structural heart-devices market. According to recent health statistics, cardiovascular diseases account for approximately 30% of all deaths in the country. This alarming trend necessitates advanced medical interventions, including structural heart devices, to manage and treat these conditions effectively. The demand for innovative solutions is further fueled by the aging population, which is more susceptible to heart-related ailments. As healthcare providers seek to improve patient outcomes, investments in the structural heart-devices market are likely to rise, reflecting a growing recognition of the need for effective treatment options. This trend indicates a robust market potential, as healthcare systems adapt to the increasing burden of cardiovascular diseases. ### Technological Innovations in Medical Devices Technological advancements in medical devices are significantly influencing the structural heart-devices market. Innovations such as minimally invasive procedures and advanced imaging techniques are enhancing the efficacy and safety of heart surgeries. For instance, the development of transcatheter aortic valve replacement (TAVR) has revolutionized treatment for aortic stenosis, allowing for reduced recovery times and improved patient outcomes. The French market is witnessing a surge in the adoption of these technologies, with a projected growth rate of around 8% annually. This growth is indicative of the healthcare sector's commitment to integrating cutting-edge technologies into patient care, thereby driving the demand for structural heart devices. As manufacturers continue to invest in research and development, the market is expected to expand further, offering a range of innovative solutions for cardiovascular treatment. ## Future Outlook The [Structural Heart Devices Market](https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385) in France is projected to grow at a 6.67% CAGR from 2025 to 2035, driven by technological advancements and increasing patient demand. **New opportunities:** - Development of minimally invasive surgical techniques for heart valve repair. - Expansion of telehealth services for remote patient monitoring. - Partnerships with healthcare providers for integrated care solutions. By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships. ## Segment Insights ### By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing) In the France structural heart-devices market, the distribution of market share among the various types of devices indicates that Transcatheter Aortic Valve Replacement (TAVR) holds a dominant position due to its widespread acceptance and effective outcomes. This segment has consistently attracted a larger portion of healthcare investments, driven by the increasing prevalence of aortic stenosis and the need for minimally invasive surgical options that enhance patient recovery. On the other hand, Mitral Valve Repair Devices are emerging as the fastest-growing segment. The rise in awareness of mitral valve disorders and advancements in technology are propelling this growth. Increased funding for research and development, combined with a growing elderly population needing surgical interventions, are significant growth drivers. These trends indicate a robust future for this segment within the broader structural heart-devices market in France. Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging) Transcatheter Aortic Valve Replacement (TAVR) is the dominant force in the France structural heart-devices market due to its established clinical efficacy and adaptability in high-risk patients. This procedure allows for valve implantation without the need for open-heart surgery, making it a preferred choice among surgeons and patients alike. In contrast, Mitral Valve Repair Devices represent an emerging segment characterized by innovative solutions aimed at addressing mitral valve insufficiency. This category includes various techniques and devices designed to restore valve function with minimal invasiveness, appealing to both healthcare providers and patients looking for advanced treatment options. As technology evolves, these segments are shaping the landscape of structural heart treatments in France. ### By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing) In the France structural heart-devices market, the distribution of procedure types reveals that minimally invasive techniques hold the largest share, driven by increased patient preference for less invasive options and quicker recovery times. Surgical procedures, although currently lower in share, are showing a notable presence as they cater to complex cases requiring significant intervention. Growth trends in this segment are primarily influenced by technological advancements, improving patient outcomes, and an aging population with heart-related conditions. Minimally invasive devices continue to lead due to their effectiveness and reduced hospital stays, while the surgical segment is catching up rapidly as techniques improve and surgical devices become more sophisticated, appealing to healthcare professionals. Minimally Invasive (Dominant) vs. Surgical (Emerging) The minimally invasive segment is characterized by its ability to provide effective treatment options with reduced trauma to patients, making it the dominant choice in the France structural heart-devices market. These devices are designed to minimize surgical incisions and enhance recovery times, leading to higher patient satisfaction. Conversely, the surgical segment, although currently emerging, is evolving due to innovations in surgical methods and equipment that address more complex cardiac conditions. As both segments progress, the surgical market is expected to expand its capabilities, drawing from advancements in minimally invasive technologies while also fostering new surgical solutions to meet patient demands. ### By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing) In the France structural heart-devices market, Aortic Stenosis is recognized as the largest segment, holding a significant share due to the high prevalence of the condition in the aging population. This segment's dominance is further solidified by the increasing adoption of advanced transcatheter interventions promoting effective treatment options for patients. Conversely, Mitral Regurgitation, although smaller in market share, is quickly gaining traction as awareness grows and newer technologies improve patient outcomes. Its rapid development is fueled by the increasing incidence rates alongside the aging demographics, leading to a rise in diagnoses and subsequent treatment of this condition. The growth trends in the indication segment are primarily driven by innovations in medical technology and a rising population of elderly patients. Aortic Stenosis benefits from advancements in catheter-based therapies, which minimize recovery times and enhance overall success rates. On the other hand, Mitral Regurgitation's growth is accelerated by the introduction of minimally invasive procedures, as well as growing research and development investments focusing on more effective treatment methods. Overall, the dynamics within the indication segment show a clear trajectory towards improving care options and addressing the unmet needs of patients suffering from structural heart conditions. Aortic Stenosis (Dominant) vs. Heart Failure (Emerging) Aortic Stenosis stands out as the dominant indication in the France structural heart-devices market, characterized by a robust presence due to the established treatment pathways and significant clinical experience with transcatheter aortic valve replacement (TAVR) methods. The market has seen a well-defined trajectory thanks to supportive reimbursement policies and a strong patient advocacy landscape. In contrast, Heart Failure is emerging as a pivotal segment, with a growing recognition of its complexity and multifactorial nature. Advances in device innovations, especially in terms of left ventricular assist devices (LVADs), are propelling this segment forward. Healthcare providers are progressively focusing on Heart Failure management and treatment options, thus enhancing its market relevance. The differentiation between these segments indicates not only their current standing but also their potential for future growth in response to evolving patient needs and technology advancements. ### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the France structural heart-devices market, hospitals dominate the end user segment, holding the largest share due to their extensive resources and capabilities in performing complex procedures. Ambulatory surgical centers, on the other hand, are gaining traction as they offer minimally invasive treatments and shorter recovery times, attracting more patients and healthcare providers alike. Growth trends indicate a shift toward outpatient procedures, which bolsters the role of ambulatory surgical centers. The increasing prevalence of heart diseases and the patient preference for less invasive solutions contribute to this growth. Moreover, advancements in technology and techniques are enhancing the efficiency and safety of these facilities, making them an attractive option for patients seeking heart treatments. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals in the France structural heart-devices market are characterized by their comprehensive treatment capabilities, including advanced diagnostic and therapeutic options. They benefit significantly from established healthcare networks, skilled professionals, and full-service amenities that facilitate the complex management of cardiovascular conditions. Conversely, ambulatory surgical centers are emerging rapidly as cost-effective alternatives. They focus on outpatient cardiac procedures, allowing for quicker turnaround times and reduced overall healthcare expenses. The rising demand for outpatient surgeries reflects a shift toward more accessible and patient-friendly care options, aided by innovations in structural heart devices that are suitable for less invasive applications. ## Competitive Benchmarking The structural heart-devices market in France is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Major players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, focusing on innovation and strategic partnerships to enhance their market presence. Edwards Lifesciences (US) emphasizes its commitment to research and development, particularly in transcatheter heart valves, while Medtronic (US) is expanding its portfolio through acquisitions and collaborations aimed at integrating digital health solutions. Abbott Laboratories (US) is also leveraging its strong R&D capabilities to introduce novel devices, thereby shaping a competitive environment that prioritizes technological superiority and patient outcomes.The market structure appears moderately fragmented, with several key players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This strategic focus on operational excellence is likely to influence competitive dynamics, as firms seek to differentiate themselves through superior service delivery and product availability. The collective influence of these major players fosters a competitive atmosphere where innovation and responsiveness to market needs are paramount. In October Edwards Lifesciences (US) announced the launch of its latest transcatheter aortic valve replacement (TAVR) system, which incorporates advanced imaging technology to improve procedural outcomes. This strategic move is significant as it not only reinforces the company's leadership in the TAVR segment but also aligns with the growing demand for minimally invasive procedures in the treatment of aortic stenosis. The integration of cutting-edge imaging capabilities is expected to enhance surgical precision, thereby potentially increasing patient safety and satisfaction. In September Medtronic (US) revealed a partnership with a leading telehealth provider to enhance remote patient monitoring for its structural heart devices. This collaboration is indicative of a broader trend towards digital health integration, allowing for real-time data collection and analysis, which could lead to improved patient management and outcomes. By leveraging telehealth solutions, Medtronic (US) aims to position itself as a pioneer in the digital transformation of cardiovascular care, thereby enhancing its competitive edge in the market. In August Abbott Laboratories (US) expanded its manufacturing capabilities in France, focusing on the production of its innovative heart valve technologies. This strategic investment not only aims to meet the rising demand for structural heart devices in Europe but also reflects Abbott's commitment to localizing production to enhance supply chain reliability. Such moves are likely to strengthen Abbott's market position while contributing to the overall growth of the structural heart-devices market in the region. As of November current trends in the structural heart-devices market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in device development and patient care. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver innovative solutions that enhance patient outcomes and operational efficiency. ## Recent News & Developments The France Structural Heart Devices Market has seen significant developments recently, with major companies like Edwards Lifesciences, Medtronic, and Boston Scientific continuing to innovate their product lines. In August 2023, Edwards Lifesciences announced the launch of a next-generation heart valve device tailored for patients with structural heart issues, highlighting its commitment to improving patient outcomes in France.  Meanwhile, Medtronic has expanded its transcatheter technologies, focusing on minimally invasive procedures that are gaining traction in French healthcare settings. Moreover, mergers and acquisitions have played a vital role in shaping the market landscape. In September 2023, Boston Scientific acquired a prominent local manufacturer of structural heart devices, combining their technologies to enhance treatment options in France.  The overall valuation of the market has been bolstered by these strategic moves, reflecting a growth trajectory amid increasing demand for advanced cardiac care. Additionally, government initiatives, including funding for innovative healthcare solutions, are further propelling the market forward, creating a robust environment for research and development in this specialized field, which has shown rapid advancements over the last few years. ## Report Scope | MARKET SIZE 2024 | 34.65(USD Million) | | --- | --- | | MARKET SIZE 2025 | 36.96(USD Million) | | MARKET SIZE 2035 | 70.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.67% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US) | | Segments Covered | Type, Procedure Type, Indication, End User | | Key Market Opportunities | Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the structural heart-devices market in France. | | Countries Covered | France | ## Frequently Asked Questions **Q: What is the current valuation of the structural heart-devices market in France as of 2024?** A: The market valuation was $34.65 Million in 2024. **Q: What is the projected market size for structural heart-devices in France by 2035?** A: The projected valuation for 2035 is $70.5 Million. **Q: What is the expected CAGR for the France structural heart-devices market during the forecast period 2025 - 2035?** A: The expected CAGR is 6.67% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the France structural heart-devices market?** A: Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, and others. **Q: What are the main segments of the structural heart-devices market in France?** A: Main segments include Transcatheter Aortic Valve Replacement, Mitral Valve Repair Devices, and others. **Q: How did the Transcatheter Aortic Valve Replacement segment perform in 2024?** A: This segment had a valuation of $12.0 Million to $25.0 Million in 2024. **Q: What is the valuation range for Mitral Valve Repair Devices in 2024?** A: The valuation for Mitral Valve Repair Devices ranged from $10.0 Million to $20.0 Million in 2024. **Q: What are the expected valuations for Left Atrial Appendage Closure Devices by 2035?** A: The expected valuation for Left Atrial Appendage Closure Devices could reach $15.0 Million by 2035. **Q: Which end users are driving the structural heart-devices market in France?** A: End users include hospitals, ambulatory surgical centers, and cardiology clinics. **Q: What is the projected growth for the Pulmonary Valve Stenosis segment by 2035?** A: The Pulmonary Valve Stenosis segment is projected to grow to $10.5 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-structural-heart-devices-market-56904*